Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
Polymorphism, Single Nucleotide
Receptor, Fibroblast Growth Factor, Type 4
Urinary Bladder Neoplasms
The impact of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism on bladder cancer is unknown. We found no clear correlations between the FGFR4 genotype and risk of bladder cancer or pathological parameters. Neither the polymorphism nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of patients.